Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.
Mattie M, Raitano A, Morrison K, Morrison K, An Z, Capo L, Verlinsky A, Leavitt M, Ou J, Nadell R, Aviña H, Guevara C, Malik F, Moser R, Duniho S, Coleman J, Li Y, Pereira DS, Doñate F, Joseph IB, Challita-Eid P, Benjamin D, Stover DR. Mattie M, et al. Among authors: joseph ib. Mol Cancer Ther. 2016 Nov;15(11):2679-2687. doi: 10.1158/1535-7163.MCT-16-0225. Epub 2016 Aug 22. Mol Cancer Ther. 2016. PMID: 27550944
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR. Pereira DS, et al. Among authors: joseph ib. Mol Cancer Ther. 2015 Jul;14(7):1650-60. doi: 10.1158/1535-7163.MCT-15-0067. Epub 2015 May 1. Mol Cancer Ther. 2015. PMID: 25934707 Free PMC article.
AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.
Doñate F, Raitano A, Morrison K, An Z, Capo L, Aviña H, Karki S, Morrison K, Yang P, Ou J, Moriya R, Shostak Y, Malik F, Nadell R, Liu W, Satpayev D, Atkinson J, Joseph IB, Pereira DS, Challita-Eid PM, Stover DR. Doñate F, et al. Among authors: joseph ib. Clin Cancer Res. 2016 Apr 15;22(8):1989-99. doi: 10.1158/1078-0432.CCR-15-1542. Epub 2015 Nov 20. Clin Cancer Res. 2016. PMID: 26589436
Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker.
Morrison K, Challita-Eid PM, Raitano A, An Z, Yang P, Abad JD, Liu W, Lortie DR, Snyder JT, Capo L, Verlinsky A, Aviña H, Doñate F, Joseph IB, Pereira DS, Morrison K, Stover DR. Morrison K, et al. Among authors: joseph ib. Mol Cancer Ther. 2016 Jun;15(6):1301-10. doi: 10.1158/1535-7163.MCT-15-0570. Epub 2016 Mar 4. Mol Cancer Ther. 2016. PMID: 26944921
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Aviña H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Doñate F, Morrison K, Stover DR. Challita-Eid PM, et al. Among authors: joseph ib. Cancer Res. 2016 May 15;76(10):3003-13. doi: 10.1158/0008-5472.CAN-15-1313. Epub 2016 Mar 24. Cancer Res. 2016. PMID: 27013195
A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates.
Ma L, Acuff NV, Joseph IB, Ptacin JL, Caffaro CE, San Jose KM, Aerni HR, Carrio R, Byers AM, Herman RW, Pavlova Y, Pena MJ, Chen DB, Buetz C, Ismaili TK, Pham HV, Cucchetti M, Sassoon I, Koriazova LK, Leveque JA, Shawver LK, Mooney JM, Milla ME. Ma L, et al. Among authors: joseph ib. Cancer Res Commun. 2024 Oct 1;4(10):2799-2814. doi: 10.1158/2767-9764.CRC-24-0278. Cancer Res Commun. 2024. PMID: 39320047 Free PMC article.
A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.
Ptacin JL, Ma L, Caffaro CE, Acuff NV, Germar K, Severy P, Qu Y, Vela JL, Cai X, San Jose KM, Aerni HR, Chen DB, Esche E, Ismaili TK, Herman R, Pavlova Y, Pena MJ, Nguyen J, Koriazova LK, Shawver LK, Joseph IB, Mooney J, Peakman M, Milla ME. Ptacin JL, et al. Among authors: joseph ib. Commun Med (Lond). 2024 Mar 26;4(1):58. doi: 10.1038/s43856-024-00485-z. Commun Med (Lond). 2024. PMID: 38532017 Free PMC article.
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism.
Ptacin JL, Caffaro CE, Ma L, San Jose Gall KM, Aerni HR, Acuff NV, Herman RW, Pavlova Y, Pena MJ, Chen DB, Koriazova LK, Shawver LK, Joseph IB, Milla ME. Ptacin JL, et al. Among authors: joseph ib. Nat Commun. 2021 Aug 9;12(1):4785. doi: 10.1038/s41467-021-24987-9. Nat Commun. 2021. PMID: 34373459 Free PMC article.
29 results